↓ Skip to Main Content
Thasso

Thasso

the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs

search: thasso

Log in | Register

Main Navigation

  • englishenglish
    • englishenglish
    • françaisfrançais
    • deutschdeutsch
    • italianoitaliano
    • españolespañol
    • portuguêsportuguês
  • thasso
  • thasso: post
  • thasso: interactions
    • thasso: community
    • thasso: video chat
    • thasso: simple chat
    • thasso: patient groups
    • thasso: forum
    • thasso: online meetings (ZOOM)
  • thasso: resources
    • theragenomics: useful links
    • theragenomics: survey at thasso
      • survey participants
    • theragenomics: biomarkers
    • theragenomics: companion tests
    • theragenomics: drug labels with annotated information
    • theragenomics: targeted therapies
    • theragenomics: drugs and genes
    • theragenomics: the world of alleles
    • theragenomics: allele-related guideline information
    • theragenomics: videos
    • drugs: interactions
    • drugs: general information
    • drugs: adverse reactions
    • drugs: risk evaluation and mitigation strategies (REMS)
  • thasso: academy
    • health authorities
      • European Medicines Agency (EMA)
      • American Food & Drug Administration (FDA)
      • Swissmedic
      • FDA Ghana
      • NAFDAC Nigeria
      • CDSCO India
      • The Medicines Control Council (MCC), South Africa
      • China Food & Drug Administration (CFDA)
      • Health Canada
    • public domain
      • Clinical Pharmacogenetics Implementation Consortium
      • ACMG Genetic Test Fact Sheets
      • Public Health Genomics Knowledge Base
      • The Human Diagnosis Project
      • Phenotypes And Genotypes Database
      • Genetic Alliance UK
      • Genetics Generation
      • Front Line Genomics
      • Alliance for Cancer Gene Therapy (ACGT)
      • EUPATI The European Patients’ Academy on Therapeutic Innovation
      • European Patient Forum
      • Uppsala Monitoring Center
      • World Health Organisation (WHO)
      • von Hippel Lindau Syndrome (VHL)
      • Cerebral Palsy Symptoms
      • Mesothelioma Fund
      • Multiple Myeloma Research Foundation
      • Open Source Pharma (OSP, Medicine for All)
    • theragenomics worldwide
      • The Human Heredity and Health in Africa (H3Africa)
      • The Asia Cohort Consortium
      • GenomeAsia 100K
    • patient & consumer health
      • ThinkGenetic
      • Consumer Health Labs
      • Exercise & Heart Disease
      • UCSF: Eating right for your heart
      • Hormones Matter
      • Living with Arthritis
      • Living with Cannabis
      • Yum of China (Foods)
    • digital therapeutics in theragenomic medicine
      • Digital Therapeutics Alliance (DTA)
      • Digital Health Alliance
    • miscellaneous
      • Partners Health Care / Personalized Medicine
      • Worst Pills / Best Pills
      • Pharmagenomics Research Network
      • Mayo Clinic: Personalized Medicine
      • Patient Power
      • Patient Opinion (UK)
      • Drug Injury Watch (Tom Lamb)
      • Ways To Fund Cancer Treatments
      • MedScape India
      • Swiss Academy of Medical Sciences
      • IDICAP: An Integrated Drug Intervention for Cancer Panel
      • PanDrugs
      • Soccer Genomics
    • companies
      • Moderna
      • BionTech
      • FDNA (Face2Gene Home)
      • IONIS Pharmaceuticals
      • Boehringer Ingelheim Home
      • Bristol-Myers Squipp Home
      • Glaxo Home
      • Novartis Home
      • Roche Home
      • AstraZeneca Home
      • Merck Home
      • Gilead Home
      • Takeda Home
      • Janssen Home
      • Novo Nordisk Home
      • Amgen Home
    • products
      • Axicabtagene ciloleucel (Yescarta)
      • Ledipasvir/Sofosbuvir (Harvoni)
      • Sofosbuvir (Sovaldi)
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Sekukinumab (Cosentyx)
      • Rivaroxaban (Xarelto)
      • Valsartan/Amlodipin/HCT (Exforge/HCT)
      • Aripiprazole (Abilify)
      • Rosuvastatin (Crestor)
      • Flibanserin (Addyi)
      • Onasemnogene abeparvovec-xioi (Zolgensma)
      • Voretigene neparvovec (Luxturna)
  • thasso: about
    • vision
    • background
    • the apomediary patient
    • disclaimers
    • policies
    • contact
  • donations $
  • Cookie Policy (EU)
Home › Posts tagged Fluoxetine [Sarafem]

Tag: Fluoxetine [Sarafem]

Avoid Coadministration of Clopidogrel [Plavix] and Omeprazole [Prilosec] or Esomeprazole [Nexium]

By Joseph Gut - thasso Posted on November 18, 2009 Posted in Drug/Drug Interaction, Pharmacogenetics Tagged with Allelic Variants, Cimetidine [Tagamet], Clopidogrel [Plavix], CYP2C19, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, Esomeprazole [Nexium], Etravirine [Intelence], Felbamate [Felbatol], Fluconazole [Diflucan], Fluoxetine [Prozac], Fluoxetine [Sarafem], Fluoxetine [Symbyax], Fluvoxamine [Luvox], Ketoconazole [Nizoral], Omeprazole [Prilosec], Ticlopidine [Ticlid], Voriconazole [VFEND]

November 17, 2009 – Today, the US Food and Drug Administration (FDA) informed on new data showing that the proton pump inhibitor (PPI) Omeprazole [Prilosec] or [Prilosec OTC] reduces the anti-blood clotting effect of Clopidogrel [Plavix] by almost half when …

Avoid Coadministration of Clopidogrel [Plavix] and Omeprazole [Prilosec] or Esomeprazole [Nexium] Read more »

In/Out

  • Log in

Optional: Social Subscribe/Login

thasso: donate

We need your help. Please support the development of thasso through donations. Thank you.    Nous avons besoin de votre aide. S'il vous plaît, vous pouvez soutenir le développement de thasso grâce à des dons. Merci.    Wir brauchen Ihre Hilfe. Bitte unterstützen Sie die Entwicklung von thasso durch Spenden. Vielen Dank.    Abbiamo bisogno del tuo aiuto. Si prega di sostenere lo sviluppo di thasso attraverso donazioni. Grazie.    Nós precisamos da sua ajuda. Por favor, apoie o desenvolvimento de thasso através de doações. Obrigada.     Necesitamos tu ayuda. Por favor apoye el desarrollo de thasso con donaciones. Muchas gracias.

thasso: conditions

thasso: newest tweets

Tweets by thasso_info

 

RSS FDA press releases

  • FDA Roundup: March 24, 2023 March 24, 2023
  • FDA Works to Further Improve Nutrition, Reduce Diet-Related Chronic Disease with Dietary Guidance Statements on Food Labels March 24, 2023
  • FDA Issues Draft Guidance Aimed at Improving Oncology Clinical Trials for Accelerated Approval March 24, 2023
  • FDA Takes Additional Steps to Improve Nutrition, Reduce Disease with Expanded Use of Salt Substitutes to Help Lower Sodium Intake March 24, 2023
  • FDA Roundup: March 21, 2023 March 21, 2023

RSS FDA MedWatch

  • Risks with Exactech Joint Replacement Devices with Defective Packaging – FDA Safety Communication March 23, 2023
  • 2023 Safety Communications March 23, 2023
  • UPDATE: Reports of Squamous Cell Carcinoma (SCC) in the Capsule Around Breast Implants - FDA Safety Communication March 22, 2023
  • Ascend Laboratories LLC. Issues Voluntary Nationwide Recall of Dabigatran Etexilate Capsules, USP 75 mg and 150 mg, Due to the Detection of N-Nitroso-dabigatran (NDAB) Impurity March 22, 2023
  • 2023 Medical Device Recalls March 17, 2023

RSS EMA Press releases

  • Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 21-22 March 2023, CVMP, 24/03/2023 March 24, 2023
  • Advancing regulatory science in the EU – mid-point report published, , 22/03/2023 March 22, 2023
  • EMA Management Board: highlights of March 2023 meeting, MB, 17/03/2023 March 17, 2023
  • Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13 - 16 March 2023, PRAC, 17/03/2023 March 17, 2023
  • Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 6-8 December 2022, CVMP, 09/12/2022 March 15, 2023

RSS random genetics

  • Researchers describe incentivized programs to aid gene therapy developers March 27, 2023
    Providing an overview of the submissions process and examples of U.S. Food and Drug Administration (FDA) applications for Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD), a new article can help developers of gene therapies for rare genetic diseases. The article is published in the journal Human Gene Therapy.
  • Study establishes link between wound fibroblasts and cancer-associated fibroblasts March 27, 2023
    A Matrix Biology paper by the Werner group (IMHS) shows how wound healing gene expression signatures are expressed in tumors and can be used to predict cancer outcome. The paper establishes a functional link between wound fibroblasts and cancer-associated fibroblasts through expression of certain extracellular matrix genes.
  • Components of cytoskeleton found to strengthen effect of sex hormones March 27, 2023
    Researchers from Freiburg and Kiel discovered that actin acts in the cell nucleus and is partly responsible for the expression of male sexual characteristics
  • Researchers delve into the mechanisms of hereditary spastic paraplegia March 27, 2023
    Researchers from the University of Seville and the Seville Institute of Biomedicine (IBiS), in collaboration with the University of Cambridge, have identified a new role for one of the genes related to hereditary spastic paraplegia. This disease is characterized by symptoms such as spasticity, paralysis and/or lack of sensation.
  • Genetic tests unexpectedly find genes linked to heart disease—now what? March 27, 2023
    Increasing use of genetic testing means people may discover they have a gene variant associated with some types of cardiovascular disease (CVD). A new scientific statement, published today in the American Heart Association journal Circulation: Genomic and Precision Medicine, aims to help individuals and health care professionals understand what to do when a variant is […]

Recent Comments

  • Joseph Gut - thasso on Is there pre-emptive genotyping to avoid adverse drug effects (ADRs)?: “Just testing. https://www.alphamannosidosis.com/en/for-patients-caregivers/disease-information/?utm_source=google&utm_medium=cpc&utm_campaign=AlphamannSearch_Paziente2020&gclid=EAIaIQobChMI2Pv7wNaC_AIVWud3Ch1J8AMPEAAYAiAAEgJGI_D_BwE/” Dec 18, 08:50
  • Joseph Gut - thasso on Including Africa in the research on rare genetic diseases: A must!: “The genetic diversity of African populations with respect to rare genetic diseases will help to better understand the mechanisms behind…” Dec 18, 04:09
  • Joseph Gut - thasso on The sixth sense: Are there genes associated with it?: “Does this now work as intended?” Dec 18, 03:55
  • David Walliams on Is genetic testing of value for ALS patients?: “CURED FROM GENITAL HERPES More than 5 years ago I was in pain with this deadly herpes virus, A few…” Nov 7, 16:08
  • Raul Malkovic on Is genetic testing of value for ALS patients?: “HOW MY WIFE GOT CURED FROM ALS Below is how i got a cure for my wife who suffered from Amyotrophic Lateral Sclerosis…” Nov 6, 21:18

Tag Cloud

Adverse Drug Reaction (ADR) African American Allelic Variant Allelic Variants American Food & Drug Administration (FDA) American Food & Drug Administration (FDA) Boxed Warning Breast Cancer Canagliflozin (Invokana) Cancer Children Committee for Medicinal Products for Human Use (CHMP) Companion Test Covid-19 Disease Diabetes Drug Induced Liver Injury (DILI) Epidermal Growth Factor Receptor (EGFR) Ethnicity European Medicine Agency (EMA) European Medicines Agency (EMA) Food and Drug Administration (FDA) Gene Therapy Genetic Background Genetic Predisposition Genetic Testing Genotype Health Canada Non-Small Cell Lung Cancer (NSCLC) Pembrolizumab [Keytruda] Personalized Medicine Phenotype Progressive Multifocal Leukoencephalopathy (PML) Rare Disease Risk Evaluation and Mitigation Strategy (REMS) SARS-CoV-2 Schizophrenia Sildenafil [Viagra] Stevens Johnson Syndrome [SJS] Targeted Therapy ThassoBase Thasso Post Theragenomic Medicine Toxic Epidermal Necrolysis (TEN) Type 2 Diabetes Vemurafenib [Zelboraf]

Meta

  • Register
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
© 2023 Thasso | Powered by Responsive Theme
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}